PMID- 35707464
OWN - NLM
STAT- MEDLINE
DCOM- 20220617
LR  - 20220724
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 13
DP  - 2022
TI  - Pathological and Prognostic Characterization of Craniopharyngioma Based on the 
      Expression of TrkA, beta-Catenin, Cell Cycle Markers, and BRAF V600E Mutation.
PG  - 859381
LID - 10.3389/fendo.2022.859381 [doi]
LID - 859381
AB  - We collected 61 craniopharyngioma (CP) specimens to investigate the expression of 
      TrkA, beta-catenin, BRAF gene mutation, and NTRK1 fusion in CP. There were 37 male 
      and 24 female individuals with a median age of 34 years (range, 4-75 years). 
      Histologically, there were 46 cases of adamantinomatous craniopharyngioma (ACP), 
      14 cases of papillary craniopharyngioma (PCP), and 1 case with a mixed 
      adamantinomatous and papillary pattern. By immunohistochemistry, we found that 
      moderate/high TrkA expression was detected in 47% (28/60) CP and was 
      significantly higher in adult patients (p = 0.018). Interestingly, TrkA is more 
      expressed in "whorled epithelium" cells in ACP, similar to the localization of 
      abnormal beta-catenin. The abnormal expression rate of beta-catenin was 70% (43/61), 
      and the medium/high cyclin D1 expression rate was 73% (44/60), both of which were 
      significantly higher in ACP than in PCP. Of the CP, 41% (21/51) had a 
      moderate/strong P16-positive signal; 58% (34/59) showed a high Ki-67 expression, 
      and there was a significant correlation between high Ki-67 L.I. and high tumor 
      recurrence (p = 0.021). NTRK1 fusion was not found in CP by fluorescence in situ 
      hybridization (FISH). By PCR, 26% (15/58) CP showed BRAF V600E gene mutation, 
      which mainly occurred in PCP (100%, 14/14) except one case of mixed CP. Moreover, 
      TrkA expression was negatively correlated with Ki-67 index and positively 
      correlated with P16 expression. There was a significantly negative correlation 
      between BRAF V600E mutation and abnormal beta-catenin expression. Our results 
      demonstrate for the first time that TrkA expression might occur in CP, especially 
      in adult CP patients, and suggest that cyclin D1 could be used for ACP 
      histological classification in addition to beta-catenin and BRAF V600E mutation, 
      while Ki-67 could be used as a marker to predict CP recurrence.
CI  - Copyright (c) 2022 Xu, Ge, Cheng, Gao, Zhang and Han.
FAU - Xu, Cheng
AU  - Xu C
AD  - Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou, China.
FAU - Ge, Songhan
AU  - Ge S
AD  - Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou, China.
FAU - Cheng, Juanxian
AU  - Cheng J
AD  - Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou, China.
FAU - Gao, Huabin
AU  - Gao H
AD  - Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou, China.
FAU - Zhang, Fenfen
AU  - Zhang F
AD  - Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou, China.
FAU - Han, Anjia
AU  - Han A
AD  - Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220530
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 0 (CTNNB1 protein, human)
RN  - 0 (Ki-67 Antigen)
RN  - 0 (NTRK1 protein, human)
RN  - 0 (beta Catenin)
RN  - 136601-57-5 (Cyclin D1)
RN  - EC 2.7.10.1 (Receptor, trkA)
RN  - EC 2.7.11.1 (BRAF protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Cell Cycle
MH  - Child
MH  - Child, Preschool
MH  - *Craniopharyngioma/genetics
MH  - Cyclin D1/genetics
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Ki-67 Antigen/genetics
MH  - Male
MH  - Middle Aged
MH  - Mutation
MH  - *Pituitary Neoplasms/diagnosis/genetics/metabolism
MH  - Prognosis
MH  - *Proto-Oncogene Proteins B-raf/genetics
MH  - *Receptor, trkA/genetics
MH  - Young Adult
MH  - *beta Catenin/genetics
PMC - PMC9190302
OTO - NOTNLM
OT  - BRAF gene mutation
OT  - Craniopharyngioma
OT  - TrkA
OT  - cyclin D1
OT  - beta-catenin
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/06/17 06:00
MHDA- 2022/06/18 06:00
PMCR- 2022/01/01
CRDT- 2022/06/16 02:39
PHST- 2022/02/19 00:00 [received]
PHST- 2022/04/20 00:00 [accepted]
PHST- 2022/06/16 02:39 [entrez]
PHST- 2022/06/17 06:00 [pubmed]
PHST- 2022/06/18 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2022.859381 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2022 May 30;13:859381. doi: 
      10.3389/fendo.2022.859381. eCollection 2022.